You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
丽珠医药(01513.HK)获多激(酉每)小分子抑制剂独家开发及商业化权利
阿思达克 09-01 09:37
丽珠医药(01513.HK)公布,集团於昨日(31日)与同源康医药签署了专利转让及技术独占许可协议,同源康医药同意授予公司就TY2136b项目(一种ROS1/NTRK/ALK多激(酉每)小分子抑制剂)及其相关专利在中国地区(包括香港、澳门和台湾地区)的独家开发及商业化权利。

公司应根据许可项目的研发进展情况支付相应的临床前研发费,总计不超过2,200万元人民币。另外公司应向同源康医药支付不低於净销售额6%的浮动型销售提成,销售提成的支付直至许可项目产品专利权到期日,或产品在许可区域内的首次上市销售起12年孰早者为止。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account